Equities Analysts Issue Forecasts for KPRX FY2024 Earnings

Posted by ABMN Staff on Nov 16th, 2024

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) – Analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Kiora Pharmaceuticals in a report released on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $1.28 per share for the year, down from their prior estimate of $1.58. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.89 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Stock Down 3.1 %

Shares of KPRX stock opened at $3.29 on Thursday. The stock has a 50-day simple moving average of $3.52 and a 200 day simple moving average of $4.27. Kiora Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last released its earnings results on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.